Non-glutamatergic clozapine augmentation strategies: a review and meta-analysis.
Author(s): Veerman SR(1), Schulte PF(2), Begemann MJ(3), de Haan L(4).
Affiliation(s): Author information:
(1)Flexible Assertive Community Treatment, Mental Health Service Organisation
North Holland North, Community Mental Health Division, Alkmaar, The Netherlands.
(2)Treatment Centre for Bipolar Disorders, Mental Health Service Organisation
North Holland North, Division for Specialised Treatment, Alkmaar, The
Netherlands. (3)Neuroscience Department & Rudolf Magnus Institute for
Neuroscience, University Medical Center Utrecht, UMCU, Utrecht, The Netherlands.
(4)Early Psychosis Department, AMC, Academic Psychiatric Centre, Amsterdam, The
Netherlands.
Publication date & source: 2014, Pharmacopsychiatry. , 47(7):231-8
Persistent negative symptoms and cognitive impairment are major clinical problems
in the treatment of schizophrenia. There is no convincing evidence regarding the
efficacy of augmentation of clozapine with a second antipsychotic, ethyl
eicosapentaenoic acid (E-EPA), an antidepressant, a mood stabilizer or extract of
Ginkgo biloba in clozapine-resistant schizophrenia. We present an overview of
studies in which the potential clinical utility of the addition of
non-glutamatergic agents to clozapine is assessed. We performed a meta-analysis
on the efficacy of both risperidone and aripiprazole compared to placebo. We
compared the effects of the addition of a second antipsychotic or an
antidepressant to clozapine on positive, negative, overall and affective symptoms
of schizophrenia in double-blind placebo-controlled trials.
|